Abstract 1452
Background
Metastasis is the main cause of death in colon cancer patients. RBP-Jκ, which is the main transcription mediator of Notch signaling, is involved in colon cancer development but its function in colon cancer metastasis is still unclear. Here we aimed to find out the function of RBP-Jκ in colon cancer metastasis and its underlying mechanisms of modulating the interaction between colon cancer cells and tumor- associated macrophages (TAMs).
Methods
Cell migration, invasion and epithelial to mesenchymal transition (EMT) were used to reflect cell metastasis ability. A oc-culture system was adopted to research the mutual regulation between colon cancer cells and TAMs. Gain- and loss-of-function experiments and TGF-β/Smad3 pathway activator and inhibitor were used to determine the underlying mechanisms of RBP-Jκ and TAMs in regulating colon cancer metastasis in vitro and in vivo. RNA sequencing was performed to find out the regulating factor between colon cancer cell and TAMs. RBP-Jκ and E-cadherin expression and TAMs infiltration were examined in 201 colon cancer patients by immunohistochemical assay and were analyzed combined with clinical parameters.
Results
RBP-Jκ and TAMs promoted colon cancer cell metastasis through the TGF-β/Smad3 pathway and secreting of TGF-β, respectively. RBP-Jκ in colon cancer cell facilitated TAMs to secret TGF-β through secreting CXCL11. RBP-Jκ and E-cadherin was highly expressed in colon cancer tissues and para-tumor tissues, respectively. And there are more TAMs infiltrated in colon cancer tissues. RBP-Jκ expression and TAMs infiltration were negatively associated with E-cadherin expression and overall survival and positively associated with metastasis. RBP-Jκ and E-cadherin expression and TAMs infiltration were independent prognostic factors in colon cancer patients.
Conclusions
Our research demonstrated that colon cancer cells with high RBP-Jκ expression secreted CXCL11 to enhance TGF-β secretion of TAMs which facilitated colon cancer metastasis. RBP-Jκ exrpression and TAMs infiltration were associated with colon cancer metastasis and acted as prognostic factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wenjuan Wang.
Funding
National Natural Science Foundation of China (No. 81502099); Key laboratory of tumor precision medicine open project of Shaanxi province (No. KLTPM-SX2018-B3); The scientific research fund of the first affiliated hospital of Xi’an Jiaotong University (2018MS-06).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5203 - Novel fusion genes identified from matched primary and recurred breast cancers by RNA-sequencing
Presenter: Soojeong Choi
Session: Poster Display session 2
Resources:
Abstract
5873 - Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer
Presenter: Donna Fitzgerald
Session: Poster Display session 2
Resources:
Abstract
3588 - The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: a translational approach.
Presenter: Anna Adam-Artigues
Session: Poster Display session 2
Resources:
Abstract
5640 - Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
Presenter: Marija Balic
Session: Poster Display session 2
Resources:
Abstract
2616 - Clinical application of mutational analysis in breast cancer patients: the relevance of PIK3CA analysis for precision medicine.
Presenter: Juan Miguel Cejalvo
Session: Poster Display session 2
Resources:
Abstract
3870 - A retrospective gene expression analysis of surgically-removed Breast Cancer Brain Metastasis (BCBM)
Presenter: Meritxell Mallafré-Larrosa
Session: Poster Display session 2
Resources:
Abstract
1240 - Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: meta-analysis of Phase II and III randomized clinical trials
Presenter: Claudia Omarini
Session: Poster Display session 2
Resources:
Abstract
5535 - Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): management and time course of key adverse events of special interest (AESIs) in SOLAR-1
Presenter: Hope Rugo
Session: Poster Display session 2
Resources:
Abstract
3093 - Changes in Hormone-Receptor status in Luminal breast cancers between primary tumor and metastases: results of the observational cohort GIM-13 AMBRA Study
Presenter: Marina Cazzaniga
Session: Poster Display session 2
Resources:
Abstract
1378 - MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)
Presenter: Miguel Martín
Session: Poster Display session 2
Resources:
Abstract